Wall Street analysts expect Stryker Co. (NYSE:SYK) to post earnings of $1.90 per share for the current fiscal quarter, according to Zacks. Ten analysts have provided estimates for Stryker’s earnings, with the lowest EPS estimate coming in at $1.89 and the highest estimate coming in at $1.92. Stryker posted earnings of $1.69 per share in the same quarter last year, which suggests a positive year over year growth rate of 12.4%. The company is scheduled to announce its next quarterly earnings results on Thursday, October 24th.

According to Zacks, analysts expect that Stryker will report full year earnings of $8.21 per share for the current year, with EPS estimates ranging from $8.15 to $8.24. For the next financial year, analysts expect that the business will report earnings of $9.01 per share, with EPS estimates ranging from $8.91 to $9.07. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that follow Stryker.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, July 25th. The medical technology company reported $1.98 EPS for the quarter, beating analysts’ consensus estimates of $1.93 by $0.05. Stryker had a return on equity of 25.98% and a net margin of 24.99%. The business had revenue of $3.65 billion during the quarter, compared to analyst estimates of $3.60 billion. During the same quarter in the prior year, the company posted $1.76 EPS. Stryker’s quarterly revenue was up 9.9% compared to the same quarter last year.

A number of brokerages have weighed in on SYK. Zacks Investment Research raised shares of Stryker from a “hold” rating to a “buy” rating and set a $225.00 target price for the company in a research note on Monday, July 29th. Canaccord Genuity increased their target price on Stryker from $195.00 to $233.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Royal Bank of Canada set a $220.00 price target on Stryker and gave the company a “buy” rating in a report on Friday, July 26th. Robert W. Baird raised their price target on Stryker from $206.00 to $239.00 and gave the company an “outperform” rating in a report on Friday, July 26th. Finally, Wells Fargo & Co lifted their price target on Stryker from $219.00 to $228.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 2nd. Five investment analysts have rated the stock with a hold rating and nineteen have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $214.89.

Shares of NYSE:SYK traded up $4.26 during trading on Friday, hitting $217.95. The stock had a trading volume of 899,005 shares, compared to its average volume of 1,208,756. The company has a quick ratio of 1.26, a current ratio of 2.07 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $81.25 billion, a PE ratio of 29.82, a PEG ratio of 2.64 and a beta of 0.83. The firm’s fifty day moving average is $216.42 and its 200 day moving average is $199.39. Stryker has a 12 month low of $144.75 and a 12 month high of $223.45.

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be given a dividend of $0.52 per share. The ex-dividend date is Friday, September 27th. This represents a $2.08 annualized dividend and a yield of 0.95%. Stryker’s dividend payout ratio (DPR) is presently 28.45%.

In related news, CFO Glenn S. Boehnlein sold 2,700 shares of Stryker stock in a transaction on Tuesday, July 30th. The shares were sold at an average price of $214.16, for a total transaction of $578,232.00. Following the transaction, the chief financial officer now owns 20,633 shares in the company, valued at approximately $4,418,763.28. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Timothy J. Scannell sold 4,666 shares of Stryker stock in a transaction on Friday, August 16th. The shares were sold at an average price of $217.08, for a total transaction of $1,012,895.28. The disclosure for this sale can be found here. Insiders have sold 20,447 shares of company stock valued at $4,262,634 in the last three months. 7.20% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently modified their holdings of the business. Farmers National Bank bought a new stake in Stryker during the 1st quarter valued at approximately $25,000. Massey Quick Simon & CO. LLC bought a new position in Stryker in the 2nd quarter worth approximately $27,000. Cable Hill Partners LLC purchased a new stake in Stryker during the 1st quarter valued at approximately $30,000. Ossiam purchased a new stake in Stryker during the 2nd quarter valued at approximately $33,000. Finally, Stonebridge Capital Advisors LLC purchased a new stake in Stryker during the 2nd quarter valued at approximately $39,000. Institutional investors and hedge funds own 73.01% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Further Reading: Quiet Period Expirations

Get a free copy of the Zacks research report on Stryker (SYK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.